Colitis clinical trials
The registry lists 127 studies for Colitis across more than 10 countries. 31 are recruiting or about to start. 34 of them are mainly about Colitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 2 narrower conditions too, such as Colitis, Ulcerative: 1,944 studies, 491 open.
Get an email when these change. Save the Colitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Janssen Research & Development, LLC (4) · M.D. Anderson Cancer Center (3) · Bausch Health Americas, Inc. (3) · Assistance Publique - Hôpitaux de Paris (3) · University of North Carolina, Chapel Hill (2) · University of Manitoba (2) · Facet Biotech (2) · Changhai Hospital (2)
What is being tested here
Drugs under test in Colitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Vedolizumab | 4 | 1 | 6 |
| Infliximab | 2 | 1 | 4 |
| Methylprednisolone | 1 | 0 | 2 |
| Prednisone | 1 | 0 | 2 |
| Vancomycin | 1 | 0 | 2 |
| Etrasimod | 1 | 0 | 2 |
| Methoxsalen | 1 | 0 | 1 |
| Pronase | 1 | 0 | 1 |
| PALI-2108 | 1 | 0 | 1 |
| Loperamide | 1 | 0 | 1 |
Drug classes tested here Corticosteroids 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5, phase 3 first
- Feb 2027Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) · Phase 3 · Radboud University Medical Center
- Feb 2027A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis · University of Minnesota
- Jun 2027Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis · Allama Iqbal Medical College
- Jun 2027A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis · Spyre Therapeutics, Inc.
- Oct 2027A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis · Palisade Bio
Who these studies take
Of the 21 Colitis studies recruiting now, 12 (57%) set no upper age limit and 8 (38%) stop at 75 or younger. 1 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (5%) | 1 (5%) |
| 18 | 20 (95%) | 20 (95%) |
| 30 | 20 (95%) | 20 (95%) |
| 40 | 20 (95%) | 20 (95%) |
| 50 | 20 (95%) | 20 (95%) |
| 65 | 19 (90%) | 19 (90%) |
| 75 | 18 (86%) | 18 (86%) |
| 85 | 13 (62%) | 13 (62%) |
Across all 127 studies, recruiting or not: 34% stop at 75 or younger and 15% at 65; 13% take children; 2% are for women only and 2% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 127. Browse all 127 → or search them.
- Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDEnrolling by invitationNCT07652294Phase 224 countries
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisRecruitingNCT07012395Phase 235 countries
- A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingNCT07470879Phase 210 countries
- A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07845487Phase 212 countries
- AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisNot yet recruitingNCT07619638Not applicable1 country
- Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)RecruitingNCT07513181Phase 21 country
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsRecruitingNCT04038619Phase 11 country
- Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)RecruitingNCT07582458Phase 2/31 country
- Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisNot yet recruitingNCT07646223Phase 21 country
- Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With CancerRecruitingNCT06337695Phase 2/31 country
- Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative ColitisEnrolling by invitationNCT07786389Phase 1/21 country
- Autologous Stem Cell Transplant for Crohn's DiseaseRecruitingNCT03219359Phase 21 country
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerRecruitingNCT03819296Phase 11 country
- Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease ManagementEnrolling by invitationNCT06424769Not applicable1 country
- A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi ArabiaRecruitingNCT075412611 country
- R-3750 in Patients With Mild to Moderate Ulcerative ColitisRecruitingNCT05666960Phase 11 country
- A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related ColitisRecruitingNCT05726396Phase 21 country
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureNot yet recruitingNCT07619898Phase 2
- Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced TherapiesRecruitingNCT07427017Phase 21 country
- KAN-004 for Immune-Related Diarrhea or ColitisRecruitingNCT07196410Phase 11 country
- FMT in Checkpoint Inhibitor-mediated Diarrhea and ColitisRecruitingNCT06206707Not applicable1 country
- Early Vedolizumab as First-Line for Immune-Related Colitis Therapy TrialRecruitingNCT06841705Phase 21 country
- Body Composition Assessment and Monitoring in Inflammatory Bowel DiseaseRecruitingNCT071627011 country
- Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for ColitisRecruitingNCT07047339Phase 2/31 country
- Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with ColitisNot yet recruitingNCT06874673Not applicable1 country
- Screening for Hepatitis Virus B Protein X (HBx) in Colitis-associated Cancer (CAC)Not yet recruitingNCT068330211 country
- Fecal Transplantation in Patients Colonic DiverticulitisNot yet recruitingNCT06254625Phase 11 country
- Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative ColitisRecruitingNCT063111231 country
- Improved and Simplified Staining Technique for Dysplasia Detection in ColitisRecruitingNCT062233471 country
- Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced ColitisRecruitingNCT05947669Phase 32 countries
- Efficacy of a Low Fiber Diet for Pediatric Colonoscopy PrepEnrolling by invitationNCT05918562Not applicable1 country
- A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT0184856121 countries
- Infliximab for Treatment of Immune Checkpoint Inhibitor ColitisActive, not recruitingNCT04305145Phase 21 country
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06598943Phase 221 countries
- Walnuts and Colon Health (The WellNut Trial)CompletedNCT05195970Not applicable1 country
- Regulation of Mucosal Healing in Inflammatory Bowel DiseaseCompletedNCT04504136Not applicable1 country
- Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel DiseaseCompletedNCT03000101Not applicable1 country
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingNCT04407247Phase 1/21 country
- Characterization of the Gut Microbiota Signature According to Physical Fitness and Its Implications for Intestinal Health.CompletedNCT072764641 country
- MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.CompletedNCT04272307Early Phase 11 country
- Optoacoustic Detection of Inflammation Using MSOT DeviceTerminatedNCT05333978Not applicable1 country
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)TerminatedNCT06137183Phase 212 countries
- The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative ColitisCompletedNCT07398586Phase 41 country
- Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisWithdrawnNCT06521762Phase 21 country
- Impact of a Physical Activity Program on Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel DiseaseCompletedNCT03774329Not applicable1 country
- Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative ColitisTerminatedNCT01671956Phase 21 country
- To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT03915769Phase 31 country
- Efficacy and Safety of Teicoplanin in CDADTerminatedNCT04003818Phase 41 country
- Kinetics and Metabolism of Nicotinamide Provided as a Dietary SupplementationCompletedNCT07156929Not applicable1 country
- Intestinal Microbiome and Chronic Inflammatory Bowel DiseaseWithdrawnNCT027680381 country